EP1178800A4 - Traitement des maladies neurodegeneratives par des inhibiteurs de l'aspartyl protease - Google Patents
Traitement des maladies neurodegeneratives par des inhibiteurs de l'aspartyl proteaseInfo
- Publication number
- EP1178800A4 EP1178800A4 EP00916643A EP00916643A EP1178800A4 EP 1178800 A4 EP1178800 A4 EP 1178800A4 EP 00916643 A EP00916643 A EP 00916643A EP 00916643 A EP00916643 A EP 00916643A EP 1178800 A4 EP1178800 A4 EP 1178800A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- methods
- protease inhibitors
- neurodegenerative disorders
- aspartyl protease
- treating neurodegenerative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12595899P | 1999-03-24 | 1999-03-24 | |
US125958P | 1999-03-24 | ||
PCT/US2000/007804 WO2000056335A1 (fr) | 1999-03-24 | 2000-03-24 | Traitement des maladies neurodegeneratives par des inhibiteurs de l'aspartyl protease |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1178800A1 EP1178800A1 (fr) | 2002-02-13 |
EP1178800A4 true EP1178800A4 (fr) | 2002-07-31 |
Family
ID=22422250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00916643A Withdrawn EP1178800A4 (fr) | 1999-03-24 | 2000-03-24 | Traitement des maladies neurodegeneratives par des inhibiteurs de l'aspartyl protease |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1178800A4 (fr) |
JP (1) | JP2002539260A (fr) |
AU (1) | AU3771700A (fr) |
CA (1) | CA2367112A1 (fr) |
WO (1) | WO2000056335A1 (fr) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001066521A1 (fr) | 2000-03-06 | 2001-09-13 | Acadia Pharmaceuticals, Inc. | Composes azacycliques utilises dans le traitement de maladies liees a la serotonine |
EP1666452A2 (fr) | 2000-06-30 | 2006-06-07 | Elan Pharmaceuticals, Inc. | Composés pour le traitement de la maladie d'Alzheimer |
PE20020276A1 (es) | 2000-06-30 | 2002-04-06 | Elan Pharm Inc | COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER |
WO2002014264A2 (fr) | 2000-08-11 | 2002-02-21 | The Brigham And Women's Hospital, Inc. | (hydroxyethyl)urees utilisees en tant qu'inhibiteurs de la production de beta-amyloide de la maladie d'alhzeimer |
US7144897B2 (en) * | 2001-06-01 | 2006-12-05 | Elan Oharmaceuticals, Inc. | Hydroxy alkyl amines |
WO2003029169A2 (fr) * | 2001-10-04 | 2003-04-10 | Elan Pharmaceuticals, Inc. | Hydroxypropylamines |
AU2002360508A1 (en) * | 2001-12-06 | 2003-06-23 | Elan Pharmaceuticals, Inc. | Substituted hydroxyethylamines |
WO2003057698A2 (fr) | 2001-12-28 | 2003-07-17 | Acadia Pharmaceuticals, Inc. | Composes spiroazacycliques utilises comme modulateurs du recepteur de monoamine |
WO2004058686A1 (fr) * | 2002-04-30 | 2004-07-15 | Elan Pharmaceuticals, Inc. | Amides hydroxypropyle pour le traitement de la maladie d'alzheimer |
US7132568B2 (en) | 2002-06-17 | 2006-11-07 | Sunesis Pharmaceuticals, Inc. | Aspartyl protease inhibitors |
US7115652B2 (en) | 2002-06-17 | 2006-10-03 | Sunesis Pharmaceuticals, Inc. | Aspartyl protease inhibitors |
IL165907A0 (en) | 2002-06-24 | 2006-01-15 | Acadia Pharm Inc | N-substituted piperidine derivatives as serotonin receptor agents |
US7538222B2 (en) | 2002-06-24 | 2009-05-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
US7253186B2 (en) | 2002-06-24 | 2007-08-07 | Carl-Magnus Andersson | N-substituted piperidine derivatives as serotonin receptor agents |
PT1587789E (pt) | 2003-01-16 | 2008-12-16 | Acadia Pharm Inc | Agonistas inversos selectivos para receptores 2a/2c da serotonina como agentes terapêuticos para doenças neurodegenerativas |
EP1644322A1 (fr) * | 2003-06-16 | 2006-04-12 | Sunesis Pharmaceuticals, Inc. | Inhibiteurs d'aspartyl-protease |
WO2005014540A1 (fr) | 2003-08-08 | 2005-02-17 | Schering Corporation | Inhibiteurs d'amines cycliques bace-1 renfermant un substituant heterocyclique |
US20050261278A1 (en) | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
US7820695B2 (en) | 2004-05-21 | 2010-10-26 | Acadia Pharmaceuticals, Inc. | Selective serotonin receptor inverse agonists as therapeutics for disease |
CN101035759B (zh) | 2004-09-27 | 2011-06-15 | 阿卡蒂亚药品公司 | N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n’-(4-(2-甲基丙氧基)苯基甲基)脲及其酒石酸盐的合成和晶形 |
US7790899B2 (en) | 2004-09-27 | 2010-09-07 | Acadia Pharmaceuticals, Inc. | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
ES2423485T3 (es) | 2007-03-19 | 2013-09-20 | Acadia Pharmaceuticals Inc. | Asociaciones de agonistas y antagonistas inversos 5-HT2A con antipsicóticos |
EP2276726A1 (fr) | 2008-04-18 | 2011-01-26 | University of Connecticut | Composés pour modulation lysosomale et procédés d utilisation |
SI3325444T1 (sl) | 2015-07-20 | 2021-11-30 | Acadia Pharmaceuticals Inc. | Postopki za pripravo N-(4-fluorobenzil)-N-(1-metilpiperidin-4-il)-N'- (4-(2-metilpropiloksi)fenilmetil)karbamida in njegove tartratne soli in polimorfne oblike C |
WO2017165635A1 (fr) | 2016-03-25 | 2017-09-28 | Acadia Pharmaceuticals Inc. | Association de pimavansérine et de modulateurs du cytochrome p450 |
US10953000B2 (en) | 2016-03-25 | 2021-03-23 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome P450 modulators |
EP3558311A1 (fr) | 2016-12-20 | 2019-10-30 | Acadia Pharmaceuticals Inc. | Pimavansérine seule ou en association pour une utilisation dans le traitement de la psychose liée à la maladie d'alzheimer |
US11135211B2 (en) | 2017-04-28 | 2021-10-05 | Acadia Pharmaceuticals Inc. | Pimavanserin for treating impulse control disorder |
US20210077479A1 (en) | 2017-08-30 | 2021-03-18 | Acadia Pharmaceuticals Inc. | Formulations of pimavanserin |
WO2020023418A1 (fr) | 2018-07-23 | 2020-01-30 | Enclear Therapies, Inc. | Méthodes de traitement de troubles neurologiques |
CA3107349A1 (fr) * | 2018-07-23 | 2020-01-30 | Enclear Therapies, Inc. | Methodes de traitement de troubles neurologiques |
EP3952947A4 (fr) | 2019-04-11 | 2024-07-03 | Enclear Therapies Inc | Procédés d'amélioration du liquide céphalorachidien et dispositifs et systèmes à cet effet |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998033795A1 (fr) * | 1997-02-04 | 1998-08-06 | The Regents Of The University Of California | Inhibiteurs de cathepsine d nanomolaires et non peptidiques |
-
2000
- 2000-03-24 AU AU37717/00A patent/AU3771700A/en not_active Abandoned
- 2000-03-24 CA CA002367112A patent/CA2367112A1/fr not_active Abandoned
- 2000-03-24 WO PCT/US2000/007804 patent/WO2000056335A1/fr active Application Filing
- 2000-03-24 EP EP00916643A patent/EP1178800A4/fr not_active Withdrawn
- 2000-03-24 JP JP2000606240A patent/JP2002539260A/ja not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998033795A1 (fr) * | 1997-02-04 | 1998-08-06 | The Regents Of The University Of California | Inhibiteurs de cathepsine d nanomolaires et non peptidiques |
Non-Patent Citations (10)
Title |
---|
CATALDO A M ET AL: "ENZYMATICALLY ACTIVE LYSOSOMAL PROTEASES ARE ASSOCIATED WITH AMYLOID DEPOSITS IN ALZHEIMER BRAIN", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 87, no. 10, 1 May 1990 (1990-05-01), pages 3861 - 3865, XP000602294, ISSN: 0027-8424 * |
CATALDO A M ET AL: "LYSOSOMAL HYDROLASES OF DIFFERENT CLASSES ARE ABNORMALLY DISTRIBUTED IN BRAINS OF PATIENTS WITH ALZHEIMER DISEASE", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 88, December 1991 (1991-12-01), pages 10998 - 11002, XP002929850, ISSN: 0027-8424 * |
CATALDO A M ET AL: "LYSOSOMAL PROTEINASE ANTIGENS ARE PROMINENTLY LOCALIZED WITHIN SENILE PLAQUES OF ALZHEIMER'S DISEASE EVIDENCE FOR A NEURONAL ORIGIN", BRAIN RESEARCH, vol. 513, no. 2, 1990, pages 181 - 192, XP001070394, ISSN: 0006-8993 * |
CATALDO ANNE M ET AL: "Colocalization of lysosomal hydrolase and beta-amyloid in diffuse plaques of the cerebellum and striatum in Alzheimer's disease and Down's syndrome.", JOURNAL OF NEUROPATHOLOGY & EXPERIMENTAL NEUROLOGY, vol. 55, no. 6, 1996, pages 704 - 715, XP001070366, ISSN: 0022-3069 * |
HAQUE, TASIR S. ET AL: "Potent, Low-Molecular-Weight Non-Peptide Inhibitors of Malarial Aspartyl Protease Plasmepsin II", J. MED. CHEM. (1999), 42(8), 1428-1440, XP000926504 * |
KENESSEY AGNES ET AL: "Degradation of tau by lysosomal enzyme cathepsin D: Implication for Alzheimer neurofibrillary degeneration.", JOURNAL OF NEUROCHEMISTRY, vol. 69, no. 5, 1997, pages 2026 - 2038, XP001069801, ISSN: 0022-3042 * |
KREUTZBERG G W: "Microglia, the first line of defence in brain pathologies.", ARZNEIMITTEL-FORSCHUNG, vol. 45, no. 3A, 1995, pages 357 - 360, XP001068957, ISSN: 0004-4172 * |
LEE, CHRISTINA E. ET AL: "General solid-phase synthesis approach to prepare mechanism-based aspartyl protease inhibitor libraries. Identification of potent cathepsin D inhibitors", J. AM. CHEM. SOC. (1998), 120(38), 9735-9747, XP002197748 * |
LI K ET AL: "ABNORMAL DISTRIBUTION OF CATHEPSIN PROTEINASES AND ENDOGENOUS INHIBITORS (CYSTATINS) IN THE HIPPOCAMPUS OF PATIENTS WITH ALZHEIMER'S DISEASE, PARKINSONISM-DEMENTIA COMPLEX ON GUAM, AND SENILE DEMENTIA AND IN THE AGED", VIRCHOWS ARCHIV A. PATHOLOGICAL ANATOMY AND HISTOPATHOLOGY, SPRINGER VERLAG, BERLIN, DE, vol. 423, no. 3, 1 September 1993 (1993-09-01), pages 185 - 194, XP002062087, ISSN: 0174-7398 * |
See also references of WO0056335A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2000056335A1 (fr) | 2000-09-28 |
CA2367112A1 (fr) | 2000-09-28 |
AU3771700A (en) | 2000-10-09 |
EP1178800A1 (fr) | 2002-02-13 |
JP2002539260A (ja) | 2002-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1178800A4 (fr) | Traitement des maladies neurodegeneratives par des inhibiteurs de l'aspartyl protease | |
AU2001238472A1 (en) | Method for treating parathyroid disorders | |
AU2001238369A1 (en) | Method for treating thyroid disorders | |
PL349192A1 (en) | Protease inhibitors | |
ZA9811830B (en) | Prodrugs of aspartyl protease inhibitors. | |
HK1046899A1 (en) | Inhibitors of aspartyl protease | |
GB9912961D0 (en) | Metalloprotease inhibitors | |
HK1045999A1 (en) | Renin inhibitors | |
AU8298801A (en) | Methods for treating atopic disorders | |
IL118657A0 (en) | Inhibitors for picornavirus proteases | |
PL362903A1 (en) | Renin inhibitors | |
AP9700961A0 (en) | Aspartyl protease inhibitors | |
IL145085A0 (en) | Dihetero-substituted metalloprotease inhibitors | |
AU5787999A (en) | Method for treating neurodegenerative disorders | |
EP1067894A4 (fr) | Inhibiteurs de protease | |
ZA97613B (en) | Aspartyl protease inhibitors | |
EP1235577A4 (fr) | Inhibiteurs de protease | |
EP1232155A4 (fr) | Inhibiteurs de protease | |
AU2001288792A1 (en) | Method of treating neurologic disorders | |
EP1229915A4 (fr) | Inhibiteurs de protease | |
EP1229914A4 (fr) | Inhibiteurs de protease | |
EP1231921A4 (fr) | Inhibiteurs de proteases | |
EP1229912A4 (fr) | Inhibiteurs de protease | |
EP1086083A4 (fr) | Inhibiteurs de proteases | |
EP1140897A4 (fr) | Inhibiteurs de proteases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20011024 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20020613 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20021022 |
|
17Q | First examination report despatched |
Effective date: 20021022 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RTI1 | Title (correction) |
Free format text: TREATMENT OF NEURODEGENERATIVE DISORDERS USING ASPARTYL PROTEASE INHIBITORS |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20071108 |